You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 66 No. 9, September 2009 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Multiple Sclerosis/ Demyelinating Disease
 •Neuro-ophthalmology
 •Diagnosis
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Diagnosis of Neuromyelitis Spectrum Disorders

Comparative Sensitivities and Specificities of Immunohistochemical and Immunoprecipitation Assays

Andrew McKeon, MB, MRCPI; James P. Fryer, MS; Metha Apiwattanakul, MD; Vanda A. Lennon, MD, PhD; Shannon R. Hinson, PhD; Thomas J. Kryzer, AS; Claudia F. Lucchinetti, MD; Brian G. Weinshenker, MD; Dean M. Wingerchuk, MD; Elizabeth A. Shuster, MD; Sean J. Pittock, MD

Arch Neurol. 2009;66(9):1134-1138.

Objective  To compare the sensitivity and specificity of immunofluorescence (IF) and immunoprecipitation (IP) assays using green fluorescent protein–tagged aquaporin-4 (AQP4) in 6335 patients for whom serological evaluation was requested on a service basis.

Design  Case-control study.

Setting  Mayo Clinic Neuroimmunology Laboratory (Rochester, Minnesota) and Departments of Neurology (Rochester, Minnesota; Scottsdale, Arizona; and Jacksonville, Florida).

Patients  Group 1, 835 Mayo Clinic patients, 100 with a neuromyelitis optica (NMO) spectrum disorder diagnosis and 735 without NMO spectrum disorder; group 2, 5500 non–Mayo Clinic patients.

Main Outcome Measure  Sensitivity and specificity of each assay for NMO or NMO spectrum disorder, individually and combined.

Results  In group 1, the sensitivity rates for NMO were IF, 58%; IP, 33%; and combined assays, 63%. The sensitivity rates for relapsing longitudinally extensive transverse myelitis were IF, 29%; IP, 6%; and combined assays, 29%. The specificity rates for NMO and relapsing longitudinally extensive transverse myelitis were IF, 99.6%; IP, 99.3%; and combined assays, 99.2%. In group 2, NMO-IgG was detected by IF in 498 of 5500 patients (9.1%) and by IP in 331 patients (6.0%); 76 of the 331 patients seropositive by IP (23%) were negative by IF. Clinical information was available for 124 patients (including 16 of those seropositive by IP only); 123 had a definite NMO spectrum disorder and 1 was at risk for NMO (monophasic optic neuritis).

Conclusions  In this large, clinical practice-based study, NMO-IgG detected by IF or IP was highly specific for NMO spectrum disorders. The IP assay was significantly less sensitive than IF. Combined testing improved sensitivity by 5%.


Author Affiliations: Departments of Neurology (Drs McKeon, Lennon, Lucchinetti, Weinshenker, and Pittock), Laboratory Medicine and Pathology (Messrs Fryer and Kryzer and Drs Lennon, Apiwattanakul, Hinson, and Pittock), and Immunology (Dr Lennon), Mayo Clinic College of Medicine, Rochester, Minnesota; Department of Neurology, Mayo Clinic, Scottsdale, Arizona (Dr Wingerchuk); and Department of Neurology, Mayo Clinic, Jacksonville, Florida (Dr Shuster).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2009;66(9):1056-1057.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Illuminating neuromyelitis optica pathogenesis
Ransohoff
Proc. Natl. Acad. Sci. USA 2012;109:1001-1002.
FULL TEXT  

Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease
Mealy et al.
Arch Neurol 2011;0:archneurol.2011.1974v1-5.
ABSTRACT | FULL TEXT  

Brain Involvement in Neuromyelitis Optica Spectrum Disorders
Chan et al.
Arch Neurol 2011;68:1432-1439.
ABSTRACT | FULL TEXT  

Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica
Kalluri et al.
Arch Neurol 2010;67:1201-1208.
ABSTRACT | FULL TEXT  

CSF GFAP: Volcanic ash from anti-aquaporin-4 antibody-mediated destruction of astrocytes
Giovannoni
Neurology 2010;75:200-201.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.